Shelly Hod Moyal
Founding Partner & Co-CEO @ iAngels
Tel Aviv, Israel
Shelly Hod Moyal is a seed investor at iAngels in Tel Aviv focused on Artificial Intelligence and Health Care. Shelly Hod Moyal is the Founding Partner and co-CEO of iAngels. She previously worked at PlainID as a SVP. Shelly Hod Moyal attended Northwestern University Kellogg School of Management.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Shelly Hod Moyal invests in
Stages Shelly Hod Moyal invests in
Countries Shelly Hod Moyal invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Artificial Intelligence 3 (27%)
- Health Care 2 (18%)
- mHealth 1 (9%)
- Robotics 1 (9%)
- Wellness 1 (9%)
Stage
- Seed 4 (36%)
- Series A 3 (27%)
- Series B 1 (9%)
Country
- Israel 3 (27%)
- United States 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| In a world that lives on digital, every business is at risk. That has been a problem for small and growing businesses, because most solutions are too cumbersome, too complicated and far too costly. That’s why we created Guardz. We curated and re-engineered the cutting-edge technology and tools that small businesses need into one, to make anaccessible, affordable way for small businesses to protect their business. We also added the ability to use their new security posture to access affordable cyber insurance. The right protection. The right price. Cybersecurity Peace of Mind. Guardz protects your business, so you can focus on building it. | $56M / Series B / Jun 09, 2025 | ||
| In a world that lives on digital, every business is at risk. That has been a problem for small and growing businesses, because most solutions are too cumbersome, too complicated and far too costly. That’s why we created Guardz. We curated and re-engineered the cutting-edge technology and tools that small businesses need into one, to make anaccessible, affordable way for small businesses to protect their business. We also added the ability to use their new security posture to access affordable cyber insurance. The right protection. The right price. Cybersecurity Peace of Mind. Guardz protects your business, so you can focus on building it. | $18M / Series A / Dec 13, 2023 | ||
| A secure platform for clarity and visibility across complex investment portfolios - Making it easy to follow the money | $6.3M / Seed / Oct 04, 2023 | ||
| Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $7M / Series A / May 31, 2023 | ||
| In a world that lives on digital, every business is at risk. That has been a problem for small and growing businesses, because most solutions are too cumbersome, too complicated and far too costly. That’s why we created Guardz. We curated and re-engineered the cutting-edge technology and tools that small businesses need into one, to make anaccessible, affordable way for small businesses to protect their business. We also added the ability to use their new security posture to access affordable cyber insurance. The right protection. The right price. Cybersecurity Peace of Mind. Guardz protects your business, so you can focus on building it. | $10M / Seed / Jan 31, 2023 | ||
| Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel. | $9M / Seed / Dec 20, 2022 | ||
| Using advanced machine vision technology and customized deep learning algorithms, Seed-X revolutionizes the entire seed breeding and production cycles.Seed-X identifies genetic traits of seeds & crops based on their phenotype features and transforms this big data into a new market standard that is remodeling the entire industry.Bringingtogether global leading experts in advanced Al technology, computer vision and deep learning combined with our genetics, biomolecular and agronomics specialists, our team is our core asset. | $10M / Series A / Jun 09, 2022 | ||
| Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $22M / Series A / Mar 22, 2022 | ||
| Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel. | $19M / Seed / Jan 11, 2022 | ||
| Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $12M / Seed / Aug 25, 2021 | ||
| See all 11 investments → | |||
Co-Investors
About iAngels
iAngels is a VC and angel investment platform that leverages due diligence and analytics to enable accredited investors around the world the ability to invest in early-stage technology deals in Israel.
iAngels Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mor Assia
Founding Partner & Co-CEO
|
|||
Tal shomron
Investor Relations Director
|
|||
David Assia
Executive Chairman
|
|||
Mirella Levy
Strategic Advisor and Partner
|
|||
|
Shelly Hod Moyal
Founding Partner & Co-CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Shelly Hod Moyal invest in?
Shelly Hod Moyal invests primarily in Artificial Intelligence, Health Care and mHealth startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shelly Hod Moyal?
Public channels for Shelly Hod Moyal include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shelly Hod Moyal last invest?
The most recent investment recorded for Shelly Hod Moyal closed in Jun 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
